Lesozap JR 15mg Tablet contains Lansoprazole, a proton pump inhibitor (PPI) indicated for the treatment of acid-related gastrointestinal conditions. Lansoprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion. Lesozap JR 15mg is primarily prescribed for the management of gastroesophageal reflux disease (GERD), erosive esophagitis, duodenal and gastric ulcers, Zollinger-Ellison syndrome, and for the eradication of Helicobacter pylori infection in combination with appropriate antibiotics. The delayed-release formulation ensures targeted delivery to the intestine, minimizing degradation by gastric acid and enhancing bioavailability. Clinical use of Lesozap JR 15mg has demonstrated significant improvement in symptom relief, mucosal healing, and ulcer resolution. The recommended dosage should be individualized based on the indication and patient response, with therapy duration typically ranging from 4 to 8 weeks. Common adverse effects include headache, abdominal pain, nausea, and diarrhea, though the medication is generally well tolerated. Caution is advised in patients with hepatic impairment, and long-term use should be monitored due to potential risks such as vitamin B12 deficiency and bone fractures. Lesozap JR 15mg should be used under medical supervision to ensure optimal therapeutic outcomes.